WallStSmart
TRDA

Entrada Therapeutics Inc

NASDAQ: TRDA · HEALTHCARE · BIOTECHNOLOGY

$14.50
+7.41% today

Updated 2026-05-01

Market cap
$503.12M
P/E ratio
P/S ratio
19.79x
EPS (TTM)
$-3.47
Dividend yield
52W range
$5 – $14
Volume
0.2M

Entrada Therapeutics Inc (TRDA) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+7.7%
Last 4 quarters
Revenue YoY growth
-96.5%
Most recent quarter
EPS YoY growth
-3233.3%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+5.0%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+10.3%
2025-11-11
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-26$-0.94+18.7%$11.98$11.93-0.4%
2025-11-11$-1.06-6.9%$7.26$8.01+10.3%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-1.16$-0.94+18.7%$1.30M-96.5%
2025-09-30$-0.99$-1.06-6.9%$1.61M-91.8%
2025-06-30$-0.82$-1.04-26.8%$1.95M-97.9%
2025-03-31$-0.78$-0.42+45.8%$20.56M-65.2%
2024-12-31$-0.67$0.03+104.5%$37.40M-10.6%
2024-09-30$-0.73$-0.35+52.1%$19.57M-55.3%
2024-06-30$0.14$1.55+1007.1%$94.69M+421.2%
2024-03-31$-0.59$0.68+215.3%$59.12M+134.0%
2023-12-31$-0.17$-0.29-70.6%$41.85M
2023-09-30$-0.74$1.02+237.8%$43.73M
2023-06-30$-0.69$-0.78-13.0%$18.17M
2023-03-31$0.97$-0.21-121.6%$25.26M

Frequently asked questions

Has Entrada Therapeutics Inc beaten earnings estimates?
Entrada Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +7.7% over the last 4 quarters.
How does TRDA stock react to earnings?
TRDA stock has moved an average of +5.0% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Entrada Therapeutics Inc's revenue growth rate?
Entrada Therapeutics Inc reported year-over-year revenue growth of -96.5% in its most recent quarter, with EPS growing -3233.3% year-over-year.